• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February

    5/24/24 12:00:24 PM ET
    $ABBV
    $ACAD
    $COR
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    U.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected individuals about their personal and highly sensitive medical information stolen during a cyberattack earlier this year. 

    The healthcare giant revealed that the breached data includes patient names, postal addresses, dates of birth, health diagnoses, and medication details.

    In letters this week, TechCrunch reported that Cencora had obtained patients’ data through partnerships with other drug makers as part of its patient support programs. 

    These partnerships include pharmaceutical companies such as AbbVie Inc (NYSE:ABBV), Acadia Pharmaceuticals Inc (NASDAQ:ACAD), Bayer AG (OTC:BAYZF) (OTC:BAYRY), Novartis AG (NYSE:NVS), and Regeneron Pharmaceuticals Inc (NASDAQ:REGN), among others.

    The nature of the cyberattack, which began on February 21, has not been disclosed. 

    After filing a notice with government regulators, Cencora publicly acknowledged the breach on February 27. 

    Despite the disclosure, the company has not revealed how many individuals were affected or how many have been notified to date. 

    Mike Iorfino, a spokesperson for Cencora, confirmed these details in an email to TechCrunch.

    This incident is the latest in a series of cyberattacks targeting the U.S. healthcare sector. Recently, UnitedHealth Group Inc (NYSE:UNH)-owned Change Healthcare and Ascension’s hospital network experienced significant breaches and operational disruptions. 

    Related: US Senate Grills United Health’s Cyberattack Fallout, Ransom Payment.

    However, Cencora maintains “no connection” between its incident and those affecting Change Healthcare and Ascension.

    As a major distributor, Cencora handles around 20% of pharmaceuticals sold and distributed in the United States.

    Read Next: US Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation.

    Price Action: COR shares are down 0.41% at $217.70 at the last check on Friday.

    Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

    Photo by Bits And Splits on Shutterstock

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $ACAD
    $COR
    $NVS

    CompanyDatePrice TargetRatingAnalyst
    UnitedHealth Group Incorporated
    $UNH
    4/7/2026$300.00Reduce → Hold
    HSBC Securities
    UnitedHealth Group Incorporated
    $UNH
    4/1/2026$330.00Mkt Perform → Outperform
    Raymond James
    Regeneron Pharmaceuticals Inc.
    $REGN
    3/31/2026$875.00Overweight
    Piper Sandler
    ACADIA Pharmaceuticals Inc.
    $ACAD
    3/25/2026$29.00Neutral → Buy
    BofA Securities
    Novartis AG
    $NVS
    3/11/2026$180.00Hold → Buy
    Argus
    Regeneron Pharmaceuticals Inc.
    $REGN
    3/6/2026$923.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    More analyst ratings

    $ABBV
    $ACAD
    $COR
    $NVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schneyer Mark C.

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    4/7/26 7:57:16 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kihara James

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    4/7/26 7:55:40 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hooper Michele J

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    4/6/26 5:04:51 PM ET
    $UNH
    Medical Specialities
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults with Rett syndrome in routine clinical practice. In support of NUPLAZID® (pimavanserin) in Parkinson's disease psychosis (PDP), Acadia will present exploratory analyses evaluating heterogeneity in treatment response trajectories

    4/17/26 9:05:00 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seabury Resources for Aging® Launches Groundbreaking Fund with Support from UnitedHealthcare to Keep Vulnerable Seniors Housed as Demand for Aging-in-Place Aid Surges

    New Housing Stabilization Fund tackles bed bug remediation, hoarding and rising utility costs for low-income residents Seabury Resources for Aging® today announced the launch of the Housing Stabilization Fund with support from UnitedHealthcare Community Plan of D.C., an innovative collaboration that delivers targeted, one-time interventions for low-income and cost-burdened District residents ages 60 and older whose housing stability is threatened by unsafe or unsanitary conditions. The fund arrives at a pivotal moment: 2026 marks the year the oldest Baby Boomers turn 80, a demographic milestone accelerating demand for aging-in-place support nationwide, even as the systems meant to suppo

    4/16/26 8:00:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

    Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb

    4/15/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CFO Rex John F bought $4,999,919 worth of shares (17,175 units at $291.12), increasing direct ownership by 9% to 203,796 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:47 PM ET
    $UNH
    Medical Specialities
    Health Care

    CEO, UHG Hemsley Stephen J bought $25,019,019 worth of shares (86,700 units at $288.57), increasing direct ownership by 15% to 679,493 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:45 PM ET
    $UNH
    Medical Specialities
    Health Care

    Director Flynn Timothy Patrick bought $491,786 worth of shares (1,533 units at $320.80) (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 12:28:22 PM ET
    $UNH
    Medical Specialities
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UnitedHealth upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded UnitedHealth from Reduce to Hold and set a new price target of $300.00

    4/7/26 8:51:26 AM ET
    $UNH
    Medical Specialities
    Health Care

    UnitedHealth upgraded by Raymond James with a new price target

    Raymond James upgraded UnitedHealth from Mkt Perform to Outperform and set a new price target of $330.00

    4/1/26 8:15:26 AM ET
    $UNH
    Medical Specialities
    Health Care

    Piper Sandler resumed coverage on Regeneron Pharma with a new price target

    Piper Sandler resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $875.00

    3/31/26 8:17:54 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    SEC Filings

    View All

    Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    4/8/26 7:05:58 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    4/3/26 4:05:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by UnitedHealth Group Incorporated

    SCHEDULE 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

    3/27/26 1:52:07 PM ET
    $UNH
    Medical Specialities
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 1, 2024 - FDA Roundup: November 1, 2024

    For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

    11/1/24 3:18:19 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    Financials

    Live finance-specific insights

    View All

    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

    Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb

    4/15/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call v

    4/1/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    AbbVie to Host First-Quarter 2026 Earnings Conference Call

    NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas

    3/31/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Announces Financial Leadership Transition

    Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de

    3/17/26 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t

    8/27/25 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $ABBV
    $ACAD
    $COR
    $NVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

    SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    11/14/24 6:48:52 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Novartis AG

    SC 13D/A - NOVARTIS AG (0001114448) (Filed by)

    10/17/24 4:01:28 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care